Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial

Author:

Cortellini Alessio1ORCID,Ricciuti Biagio2,Borghaei Hossein3ORCID,Naqash Abdul Rafeh4,D'Alessio Antonio15,Fulgenzi Claudia A. M.16,Addeo Alfredo7,Banna Giuseppe L.89,Pinato David James110ORCID

Affiliation:

1. Division of Cancer, Department of Surgery and Cancer Imperial College London London UK

2. Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute Harvard Medical School Boston Massachusetts USA

3. Department of Hematology–Oncology, Fox Chase Cancer Center Temple University Health System Philadelphia Pennsylvania USA

4. Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center University of Oklahoma Oklahoma City Oklahoma USA

5. Department of Biomedical Sciences Humanitas University Pieve Emanuele (Milan) Italy

6. Department of Medical Oncology University Campus Bio‐Medico of Rome Rome Italy

7. Oncology Department University Hospital of Geneva Geneva Switzerland

8. Candiolo Cancer Institute, FPO‐IRCCS Turin Italy

9. Portsmouth Hospitals University NHS Trust Portsmouth UK

10. Department of Translational Medicine, Università del Piemonte Orientale “A. Avogadro,” Novara Italy

Funder

Imperial College Healthcare NHS Trust

Cancer Research UK

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3